September 21, 2017 8:19 AM ET

Pharmaceuticals

Company Overview of Daiichi Sankyo, Inc.

Company Overview

Daiichi Sankyo, Inc. develops and markets pharmaceuticals. The company offers therapies in the areas of hypertension, dyslipidemia, diabetes, acute coronary syndrome, metastatic melanoma, cardiology, oncology, pain, and other aspects. It serves customers in the United States and internationally. Daiichi Sankyo, Inc. was formerly known as Sankyo Pharma Inc. and changed its name to Daiichi Sankyo, Inc. in April 2006. The company was founded in 1996 and is based in Parsippany, New Jersey. Daiichi Sankyo, Inc. operates as a subsidiary of Daiichi Sankyo Company, Limited.

Two Hilton Court

Suite 2

Parsippany, NJ 07054

United States

Founded in 1996

Phone:

973-359-2600

Fax:

973-359-2645

Key Executives for Daiichi Sankyo, Inc.

Executive Chairman & President
Vice President of Operations
Chief Executive Officer of Daiichi Sankyo Co., Ltd. and President of Daiichi Sankyo Co., Ltd.
Age: 67
Global Head of Development and Executive Vice President
Global Head of Oncology Research & Development and Executive Vice President
Compensation as of Fiscal Year 2017.

Daiichi Sankyo, Inc. Key Developments

Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. Announce Settlement Agreement on U.S. Products Liability Litigation

Daiichi Sankyo Company, Limited and Daiichi Sankyo, Inc. announced that they have agreed to enter into a program to settle, on behalf of all defendants, pending product liability litigation against various Daiichi Sankyo and Forest entities. These cases are related to olmesartan products (Benicar, Benicar HCT, Azor and Tribenzor) and allegations that such products caused sprue-like enteropathy and other severe gastro-intestinal symptoms. The lawsuits were filed beginning in January 2014. The settlement requires, among other thresholds, that at least 95% of all eligible litigants and claimants decide to opt-in to the settlement under certain conditions. Claimants eligible to opt-in to the settlement program, under certain conditions, include those with claims already filed in court (currently almost 2300 cases) and those with certain unfiled claims. Once the agreed-upon thresholds are met, and following a review of claims by a Claims Administrator, claimants who meet specified criteria will receive payouts from the settlement fund, which is capped at $300 million. A portion of the capped amount will also be used for plaintiffs' counsel fees and expenses and the cost of the Claims Administrator as per the settlement agreement.

Daiichi Sankyo, Inc. Presents at 5th Annual Cancer BioPartnering & Investment Forum, Mar-28-2017 08:40 AM

Daiichi Sankyo, Inc. Presents at 5th Annual Cancer BioPartnering & Investment Forum, Mar-28-2017 08:40 AM. Venue: New York Academy of Sciences, New York, New York, United States. Speakers: William Kuziel, Director, External Scientific Affairs.

Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108

Charleston Laboratories, Inc., and Daiichi Sankyo, Inc., confirmed that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CL-108 (hydrocodone, acetaminophen, promethazine), an investigational treatment for the management of pain severe enough to require an opioid analgesic while preventing or reducing the associated opioid-induced nausea and vomiting when alternative treatments for pain are inadequate. The CRL stated that the NDA in its present form was not approved and provided guidance on information needed to resolve matters identified. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. intend to work closely with the FDA to address the points raised in this action.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
August 7, 2017
Kahua, Inc.
Merger/Acquisition
April 3, 2017
Daiichi Sankyo, Inc., Pharmaceutical Packaging Facility in Bethlehem, Pennsylvania
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Daiichi Sankyo, Inc., please visit dsi.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.